Cancer-Associated Venous Thromboembolism — Beyond 6 Months

Venous thromboembolism is a common complication of cancer and its treatments, and the incidence of recurrent thrombosis, serious bleeding, and death is higher among patients with this condition than in the general population. More than 20 years have passed since Lee et al.1 reported the results of the landmark CLOT trial in the Journal. This trial showed the superior efficacy of dalteparin over vitamin K antagonists in the prevention of recurrent venous thrombosis in patients with cancer, and it established a 6-month course of weight-adjusted low-molecular-weight heparin as standard care for cancer-associated thrombosis. Much has changed since the CLOT trial. . . .